Abstract Library

#2083 Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study

Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kjellman M

Authors: Kjellman M, Knigge u, Welin S, Grønbæk H, Thiis-Evensen E,

Keywords: Plasma Protein Biomarker,

#1762 Prevalence of Carcinoid Heart Disease in Patients with Disseminated Small Intestinal NET

Introduction: In patients with small intestinal neuroendocrine tumours (SI-NETs), serotonin may induce fibrosis and lead to carcinoid heart disease (CHD) with right sided valvular dysfunction.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Groenbaek H

Authors: Dam G, Rasmussen V, Oksjoki R, Villadsen G, Grønbæk H,

Keywords: carcinoid heart disease, SI-NET,

#913 A PCR-Based Multigene Transcript Analysis Blood Test Outperforms Chromogranin A in the Detection of Gastrointestinal and Pancreatic Neuroendocrine Tumors and is Unaffected by PPI Use or Hypertension

Introduction: A critical requirement in the management of gut NETs is a blood biomarker test that is sensitive, specific and reproducible.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Modlin I

Authors: Modlin I, Kidd M, Drozdov I, Aslanian H, Alaimo D,

Keywords: biomarker, CgA, NET, PCR,

#784 Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumors in a Danish NET Center

Introduction: Small intestinal neuroendocrine tumors (NET) have increased in incidence during the past decades. However, time trends from the Nordic countries are sparse.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Grønbæk H

Authors: Høj L, Nykjær K, Grønbæk H,

Keywords: neuroendocrine tumor, imaging, chromogranin A,

#678 Management of Patients with Neuroendocrine Tumors: Case Presentations Including Long-term, Open-label Pasireotide

Introduction: The somatostatin analog (SSA) pasireotide long-acting release (pasireotide LAR) is under investigation for the treatment of patients (pts) with NET and carcinoid disease refractory or resistant to available SSA.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Wolin E

Authors: Wolin E, Giannone V, Hermasillo Resendiz K,

Keywords: somatostatin analog, pasireotide, carcinoid syndrome,